Evidence map›Paper›PMID 42662922›Full record

ArticleMolecular therapy. Nucleic acids2026

Givinostat enhances antisense oligonucleotide efficacy in the

Xaysongkhame Phongsavanh, Cecile Gastaldi, Astrid Mottais, Mathilde Doisy, Olivier Le Coz, Sandra de Haan, Pietro Spitali, Luis Garcia, Aurélie Goyenvalle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xaysongkhame PhongsavanhUniversité Paris-Saclay, UVSQ, Inserm, IMPROVE, 78000 Versailles, France.
Cecile GastaldiMedical Biology Department, Centre Scientifique de Monaco, 98000 Principality of Monaco, MC, Monaco.
Astrid MottaisUniversité Paris-Saclay, UVSQ, Inserm, IMPROVE, 78000 Versailles, France.
Mathilde DoisyUniversité Paris-Saclay, UVSQ, Inserm, IMPROVE, 78000 Versailles, France.
Olivier Le CozUniversité Paris-Saclay, UVSQ, Inserm, IMPROVE, 78000 Versailles, France.
Sandra de HaanDepartment of Human Genetics, Leiden University Medical Center, Leiden ZA 2333, the Netherlands.
Pietro SpitaliDepartment of Human Genetics, Leiden University Medical Center, Leiden ZA 2333, the Netherlands.
Luis GarciaLIA BAHN, CSM-UVSQ, Principality of Monaco, Monaco.
Aurélie GoyenvalleUniversité Paris-Saclay, UVSQ, Inserm, IMPROVE, 78000 Versailles, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder caused by mutations in the

Indexed as

antisense oligonucleotidesDuchenne muscular dystrophyexon-skippinggivinostathistone deacetylase inhibitorsmdx52MT: oligonucleotides: therapies and applicationstranscript imbalance

Identifiers

PMID42662922
PMCPMC13521170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.